$CADL

Candel Therapeutics 1Q 2026: Net income $(8.9)M, EPS $(0.14) — 10-Q Summary

Candel Therapeutics reported a net loss of $(8.9)M and diluted EPS of $(0.14) for Q1 2026, a significant downturn from the previous year's positive figures. Despite the financial loss, the company highlighted several business advancements, including positive Phase 3 prostate trial data, progress in NSCLC programs, and ongoing clinical momentum for other therapies. Candel Therapeutics is also preparing for a potential prostate launch and scaling up manufacturing.

Original reporting
Published May 14, 2026, 12:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 14, 2026, 1:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CADL
Bearish
medium confidence
Mentioned
$CADL
alphai data visualization · based on TradingView
Decision brief

The 30-second read

$CADLBearishLow
01

Why it matters

The financial loss may weigh on investor sentiment, but clinical progress and upcoming product launches could offset concerns, leading to mixed market reactions.

02

Market read

Limited immediate trading impact due to financial losses, but clinical advancements provide potential for future positive developments.

03

What to watch

Potential partnership announcements or regulatory approvals could significantly alter the stock's trajectory, which are not reflected in current data.

Timing: short-term

Background

Candel Therapeutics reported a net loss of $8.9 million and EPS of -$0.14 for Q1 2026, marking a downturn from previous positive earnings. Despite financial challenges, the company announced positive Phase 3 prostate trial data, progress in NSCLC programs, and preparations for a prostate launch, indicating ongoing clinical momentum.

Company-level read

Ticker impact

$CADLBearishMedium confidence
Context

The news about Candel Therapeutics (CADL) primarily impacts the biotech and life sciences sectors, with limited direct influence on CADL's stock performance due to its specific focus on clinical trial results and financials.

Expected impact

Potential short-term decline followed by stabilization as clinical progress is recognized; long-term outlook remains uncertain pending financial turnaround.

Evidence & confidence

Financial losses and bearish sentiment suggest cautious trading; however, positive clinical data could mitigate downside risks.

Market effects

The biotech sector may experience slight volatility due to clinical trial updates and financial results of key players like Candel Therapeutics.

Limited regional impact; primarily affects US biotech stocks.

Minimal global market relevance given the company's size and sector.

Counterpoint

Positive clinical trial data and upcoming product launches could lead to a rebound in CADL's stock, presenting a buying opportunity for patient investors.

Key entities

  • Candel Therapeutics

    A biotech firm focused on cancer immunotherapies and clinical trials.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.